by Ganesh Suntharalingam, Honorary Secretary, Intensive Care Society
On the morning of Monday 13 March 2006, six out of eight healthy male volunteers on a clinical trial received a first dose of a drug never before given to humans, in an independent commercially-run clinical trials unit within the grounds of Northwick Park Hospital.
This was planned and expected to be completely routine. However, all six men had a life-threatening reaction requiring an emergency response by the NHS, which not only had a lasting impact on them but also brought about changes in how higher-risk clinical trials are run and regulated in the UK, EU, and beyond.
Saving the lives of those volunteers Continue reading “[Long Read] The TGN1412 drug trial: A personal view”